New cocktail aims to stall lung cancer progression
NCT ID NCT04716933
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This Phase 3 trial tested whether adding the targeted drug lenvatinib to standard chemotherapy plus the immunotherapy pembrolizumab helps people with advanced nonsquamous non-small cell lung cancer live longer without their cancer growing. The study enrolled 201 adults in China who had not received prior treatment for their metastatic disease. Researchers measured how long participants lived and how long until their cancer worsened.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- lenvatinib (a targeted cancer drug taken as a capsule)
- What this could lead to
- If successful, adding lenvatinib could help people with this type of lung cancer live longer without their disease getting worse.
- What could go wrong
- This is a relatively small Phase 3 trial (201 participants) from one country, so results may not apply broadly. Adding lenvatinib also increases the chance of side effects like high blood pressure or fatigue.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NONSQUAMOUS NON SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Cancer Hospital ( Site 0120)
Beijing, Beijing Municipality, 100036, China
-
Cancer Hospital Affiliated to Xinjiang Medical University ( Site 0110)
Urumuqi, Xinjiang, 830000, China
-
Cancer Hospital Chinese Academy of Medical Science ( Site 0117)
Beijing, Beijing Municipality, 100021, China
-
First Affiliated Hospital of The Third Military Medical University ( Site 0118)
Chongqing, Chongqing Municipality, 400038, China
-
Fujian Provincial Cancer Hospital ( Site 0102)
Fuzhou, Fujian, 350014, China
-
Henan Cancer Hospital ( Site 0112)
Zhengzhou, Henan, 450008, China
-
Hubei Cancer Hospital ( Site 0122)
Wuhan, Hubei, 430079, China
-
Jilin Cancer Hospital ( Site 0115)
Changchun, Jilin, 130103, China
-
Peking Union Medical College Hospital ( Site 0108)
Beijing, Beijing Municipality, 100006, China
-
Shanghai Pulmonary Hospital ( Site 0101)
Shanghai, Shanghai Municipality, 200443, China
-
Southern Medical University Nanfang Hospital ( Site 0121)
Guangzhou, Guangdong, 510515, China
-
The First Affiliated Hospital Zhejiang University ( Site 0109)
Hangzhou, Zhejiang, 310003, China
-
The First Affiliated Hospital of Wenzhou Medical University ( Site 0124)
Wenzhou, Zhejiang, 325000, China
-
The Second Hospital Affiliated to AMU ( Site 0119)
Chongqing, Chongqing Municipality, 400037, China
-
The Third Affiliated Hospital of Harbin Medical University ( Site 0100)
Harbin, Heilongjiang, 150081, China
-
Tianjin Medical University Cancer Institute & Hospital ( Site 0111)
Tianjin, Tianjin Municipality, 300060, China
-
Wuhan Union Hospital ( Site 0123)
Wuhan, Hubei, 430022, China
-
Zhejiang Cancer Hospital ( Site 0113)
Hangzhou, Zhejiang, 310022, China
-
Zhongshan Hospital Fudan University ( Site 0103)
Shanghai, Hunan, 200032, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.